Security
Trevi Therapeutics, Inc. Common Stock · TRVI
TRVINASDAQCommon stockCurrentCIK 1563880Updated Oct 28, 2026
TRVI price & chart
Loading TradingView…
NASDAQ:TRVI on TradingView ↗About the company
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
In the news
Trevi Therapeutics to Participate in Upcoming August Conferences ↗
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates News provided by Trevi Therapeutics, Inc. Nov 13, 2025, 16:05 ET Share this article Share to X Share this article Share to X Company preparing to initiate comprehensive Phase 3 program for chronic cough in ↗
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 News provided by Trevi Therapeutics, Inc. Nov 06, 2025, 16:05 ET Share this article Share to X Share this article Share to X Conference call and webcast to be held at 4:30 p.m. ET NE ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 199,356,000Source | 68,908,000Source | 330,518,000Source | 208,339,000Source | 73,810,000Source | 179,606,000Source | 107,004,000Source | 78,559,000Source | 193,439,000Source | 110,900,000Source | 89,403,000Source | 123,015,000Source |
| Property, Plant and Equipment, NetUSD | 213,000Source | 174,000Source | 336,000Source | 239,000Source | 198,000Source | 265,000Source | 277,000Source | 204,000Source | 178,000Source | 157,000Source | 216,000Source | 170,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 56,869,000Source | 16,052,000Source | 54,302,000Source | 117,058,000Source | 12,963,000Source | 19,412,000Source | 19,374,000Source | 13,811,000Source | 18,914,000Source | 34,097,000Source | 32,397,000Source | 12,589,000Source |
| Assets, CurrentUSD | 198,299,000Source | 67,336,000Source | 325,705,000Source | 207,228,000Source | 72,129,000Source | 176,121,000Source | 105,621,000Source | 76,766,000Source | 191,656,000Source | 109,428,000Source | 87,547,000Source | 122,616,000Source |
| Operating Lease, Right-of-Use AssetUSD | 741,000Source | 973,000Source | 542,000Source | 804,000Source | 1,029,000Source | 610,000Source | 865,000Source | 1,084,000Source | 677,000Source | 915,000Source | 1,137,000Source | 24,000Source |
| Other Assets, NoncurrentUSD | 103,000Source | 256,000Source | 3,935,000Source | 68,000Source | 273,000Source | 2,610,000Source | 241,000Source | 311,000Source | 928,000Source | 243,000Source | 297,000Source | 205,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 9,568,000Source | 9,939,000Source | 9,012,000Source | 9,846,000Source | 7,636,000Source | 7,479,000Source | 7,547,000Source | 6,225,000Source | 10,195,000Source | 11,256,000Source | 6,856,000Source | 15,556,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 128,000Source | 75,000Source | 142,000Source | 122,000Source | 73,000Source | 128,000Source | 100,000Source | 69,000Source | 128,000Source | 94,000Source | 68,000Source | 60,000Source |
| Additional Paid in CapitalUSD | 511,118,000Source | 334,385,000Source | 682,582,000Source | 508,033,000Source | 328,573,000Source | 515,185,000Source | 396,669,000Source | 322,368,000Source | 512,772,000Source | 386,534,000Source | 321,642,000Source | 317,590,000Source |
| Retained Earnings (Accumulated Deficit)USD | -321,488,000Source | -275,630,000Source | -360,793,000Source | -309,686,000Source | -262,388,000Source | -342,996,000Source | -297,385,000Source | -250,036,000Source | -329,804,000Source | -287,045,000Source | -239,134,000Source | -210,069,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 30,000Source | 139,000Source | -425,000Source | 24,000Source | -84,000Source | -190,000Source | 73,000Source | -67,000Source | 148,000Source | 61,000Source | -29,000Source | -122,000Source |
| Stockholders' Equity Attributable to ParentUSD | 189,788,000Source | 58,969,000Source | 321,506,000Source | 198,493,000Source | 66,174,000Source | 172,127,000Source | 99,457,000Source | 72,334,000Source | 183,244,000Source | 99,644,000Source | 82,547,000Source | 107,459,000Source |
| Liabilities and EquityUSD | 199,356,000Source | 68,908,000Source | 330,518,000Source | 208,339,000Source | 73,810,000Source | 179,606,000Source | 107,004,000Source | 78,559,000Source | 193,439,000Source | 110,900,000Source | 89,403,000Source | 123,015,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 9,041,000Source | 9,123,000Source | 8,736,000Source | 9,241,000Source | 6,752,000Source | 7,115,000Source | 6,866,000Source | 5,276,000Source | 9,749,000Source | 10,509,000Source | 5,824,000Source | 13,400,000Source |
| Operating Lease, Liability, CurrentUSD | 296,000Source | 235,000Source | 329,000Source | 286,000Source | 216,000Source | 318,000Source | 276,000Source | 198,000Source | 307,000Source | 254,000Source | 184,000Source | 25,000Source |
| Accounts Payable, CurrentUSD | 2,709,000Source | 1,614,000Source | 3,098,000Source | 2,974,000Source | 1,511,000Source | 2,215,000Source | 1,421,000Source | 2,112,000Source | 3,911,000Source | 3,414,000Source | 1,809,000Source | 2,857,000Source |
| Operating Lease, Liability, NoncurrentUSD | 527,000Source | 816,000Source | 276,000Source | 605,000Source | 884,000Source | 364,000Source | 681,000Source | 949,000Source | 446,000Source | 747,000Source | 1,001,000Source | 2,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 3,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 6,036,000Source | 7,212,000Source | 5,309,000Source | 5,981,000Source | 4,932,000Source | 4,582,000Source | 5,169,000Source | 2,842,000Source | 5,531,000Source | 6,810,000Source | 3,709,000Source | 3,518,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 34,000Source | 37,000Source | 144,000Source | 147,000Source | 123,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 1,243,000Source | 822,000Source | 3,272,000Source | 1,384,000Source | 2,191,000Source | 1,208,000Source | 5,185,000Source | 3,588,000Source | 2,247,000Source | 2,327,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,483,000Source | -1,993,000Source | -598,000Source | 1,605,000Source | -1,049,000Source | 9,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -16,689,000Source | -13,477,000Source | -42,089,000Source | -38,256,000Source | -31,710,000Source | -28,175,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 16,965,000Source | -9,951,000Source | -94,107,000Source | -21,528,000Source | 59,428,000Source | -107,373,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 102,000Source | — | 12,000Source | 35,000Source | 137,000Source | 159,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 222,000Source | 8,705,000Source | 121,013,000Source | 61,484,000Source | -7,910,000Source | 111,307,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 5,833,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 498,000Source | -14,723,000Source | -15,183,000Source | 1,700,000Source | 19,808,000Source | -24,241,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 56,869,000Source | 16,052,000Source | 54,302,000Source | 117,058,000Source | 19,412,000Source | 19,374,000Source | 18,914,000Source | 34,097,000Source | 32,397,000Source | 12,589,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 4,000Source | 331,000Source | 594,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | -33,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | — | 180,000Source | 520,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 132,000Source | 94,000Source | 81,000Source | 43,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | -7,000Source | — | -10,000Source | — |
| General and Administrative ExpenseUSD | — | — | 3,831,000Source | 2,863,000Source | 5,357,000Source | 4,333,000Source | 4,971,000Source | 3,659,000Source | 15,850,000Source | 12,147,000Source | 10,240,000Source | 10,073,000Source |
| Income Tax Expense (Benefit)USD | — | — | -15,000Source | -31,000Source | -19,000Source | -21,000Source | -20,000Source | -11,000Source | -64,000Source | -30,000Source | -32,000Source | -36,000Source |
| InterestExpenseNonoperatingUSD | — | — | 0Source | 1,000Source | — | 0Source | — | — | 0Source | 4,000Source | — | — |
| Investment Income, InterestUSD | — | — | 2,101,000Source | 826,000Source | 2,696,000Source | 1,407,000Source | 1,696,000Source | 1,125,000Source | 6,536,000Source | 3,602,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,802,000Source | -13,242,000Source | -17,797,000Source | -12,301,000Source | -13,192,000Source | -10,340,000Source | -42,759,000Source | -47,911,000Source | -29,065,000Source | -29,152,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,099,000Source | 814,000Source | 2,693,000Source | 1,400,000Source | 1,700,000Source | 1,119,000Source | 6,505,000Source | 3,583,000Source | 4,826,000Source | 719,000Source |
| Operating ExpensesUSD | — | — | 13,916,000Source | 14,087,000Source | 20,509,000Source | 13,722,000Source | 14,912,000Source | 11,470,000Source | 49,328,000Source | 51,524,000Source | 33,923,000Source | 29,907,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -2,000Source | -11,000Source | -3,000Source | -7,000Source | 4,000Source | -6,000Source | -31,000Source | -15,000Source | 469,000Source | 289,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 21,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 25,552,000Source | 17,595,000Source | 76,567,000Source | 76,970,000Source | 69,497,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 222,000Source | 718,000Source | 2,079,000Source | 394,000Source | 74,000Source | 139,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -13,916,000Source | -14,087,000Source | -20,509,000Source | -13,722,000Source | -14,912,000Source | -11,470,000Source | -49,328,000Source | -51,524,000Source | -33,923,000Source | -29,907,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -2,000Source | -11,000Source | -3,000Source | -7,000Source | 4,000Source | -6,000Source | -31,000Source | -15,000Source | 469,000Source | 289,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -11,817,000Source | -13,273,000Source | -17,816,000Source | -12,322,000Source | -13,212,000Source | -10,351,000Source | -42,823,000Source | -47,941,000Source | -29,097,000Source | -29,188,000Source |
| Income Tax Expense (Benefit)USD | — | — | -15,000Source | -31,000Source | -19,000Source | -21,000Source | -20,000Source | -11,000Source | -64,000Source | -30,000Source | -32,000Source | -36,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,802,000Source | -13,242,000Source | -17,797,000Source | -12,301,000Source | -13,192,000Source | -10,340,000Source | -42,759,000Source | -47,911,000Source | -29,065,000Source | -29,152,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.08Source | -0.13Source | -0.11Source | -0.09Source | -0.09Source | -0.09Source | -0.32Source | -0.47Source | -0.29Source | -0.45Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.08Source | -0.13Source | -0.11Source | -0.09Source | -0.09Source | -0.09Source | -0.32Source | -0.47Source | -0.29Source | -0.45Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 145,104,986Source | 101,282,228Source | 156,602,158Source | 130,350,391Source | 145,592,901Source | 117,610,750Source | 134,747,198Source | 101,971,873Source | 99,033,373Source | 64,541,911Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 145,104,986Source | 101,282,228Source | 156,602,158Source | 130,350,391Source | 145,592,901Source | 117,610,750Source | 134,747,198Source | 101,971,873Source | 99,033,373Source | 64,541,911Source |
| Interest Expense (non-operating)USD | — | — | 0Source | 1,000Source | — | 0Source | — | — | 0Source | 4,000Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 3,831,000Source | 2,863,000Source | 5,357,000Source | 4,333,000Source | 4,971,000Source | 3,659,000Source | 15,850,000Source | 12,147,000Source | 10,240,000Source | 10,073,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 391,000Source | 1,163,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | — | — | — | — | — | — | 4,748,000Source | 1,740,000Source |
| Investment Income, InterestUSD | — | — | 2,101,000Source | 826,000Source | 2,696,000Source | 1,407,000Source | 1,696,000Source | 1,125,000Source | 6,536,000Source | 3,602,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 2,099,000Source | 814,000Source | 2,693,000Source | 1,400,000Source | 1,700,000Source | 1,119,000Source | 6,505,000Source | 3,583,000Source | 4,826,000Source | 719,000Source |
| Operating ExpensesUSD | — | — | 13,916,000Source | 14,087,000Source | 20,509,000Source | 13,722,000Source | 14,912,000Source | 11,470,000Source | 49,328,000Source | 51,524,000Source | 33,923,000Source | 29,907,000Source |
| Research and Development ExpenseUSD | — | — | 10,085,000Source | 11,224,000Source | 15,152,000Source | 9,389,000Source | 9,941,000Source | 7,811,000Source | 33,478,000Source | 39,377,000Source | 23,683,000Source | 19,834,000Source |
Filing attachments
trvi-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 trvi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 Initiated Phase 2b LAKE trial for patients with refractory chronic cough in the second quarter; sample size re-estimation expected in the fourth …
Read attachment ↗trvi-ex99_1.htm · 8-K · 2026-05-05
EX-99.1 2 trvi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued pipeline advancement Clinical development plans remain on track across all chronic cough indications Management to host a conference call …
Read attachment ↗d587027dex991.htm · 8-K · 2026-04-17
EX-99.1 4 d587027dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock New Haven, Conn., April 16, 2026 - Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chro…
Read attachment ↗trvi-ex99_1.htm · 8-K · 2026-03-17
EX-99.1 2 trvi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026 C…
Read attachment ↗trvi-ex99_1.htm · 8-K · 2025-11-13
EX-99.1 2 trvi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company ended the third quarter of 2025 with $194.9 million in cash, cash equivalents and marketable securities with expected cash runway into 2028 Management to host a conference call and webcas…
Read attachment ↗trvi-ex99_1.htm · 8-K · 2025-08-07
EX-99.1 2 trvi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET New Haven, Conn., August 7, 2025 - Trevi Therapeutics, Inc.…
Read attachment ↗